Abstract
Objective: To study the relationship between the expression of serum human leucocyte antigen-G5 (HLA-G5)/soluble CD30 (sCD30) and the fuction of renal graft in kidney transplant recipients and investigate the immune status of recipients with combined HLA-G5 and sCD30. Methods: From January 2002 to November 2008, a total of 66 kidney transplant recipients in our centre were selected as subjects and divided into three groups; stable function of renal graft (n=38), acute rejection (n=15) and chronic rejection (n=13). The expressions of serum HLA-G5 and sCD30 were detected. There were two different immune conditions with acute/chronic allograft rejection and normal renal graft in kidney transplant recipients as evaluated by combined HLA-G5 and sCD30.The sensitivity, specificity and critical value of the method were analyzed by the curve of receiver operating characteristic. Results: The levels of HLA-G5 and sCD30 were significantly correlated with serum creatinine (r=-0.493, 0.691, both P < 0.01). Within the first year post-transplantation, the sensitivity was 78.6% and the specificity 85.7% when HLA-G5 critical value 82 μg/L and sCD30 critical value 12.2 μg/L. After one year post-transplantation: the sensitivity was 92.3% and the specificity 84.6% when HLA-G5 critical value 141 μg/L and sCD30 critical value 10.3 μg/L. Conclusion: The immune state of recipients are evaluated by combine HLA-G5 and sCD30 which may be a simple and valid method.
| Original language | English |
|---|---|
| Pages (from-to) | 2528-2531 |
| Number of pages | 4 |
| Journal | National Medical Journal of China |
| Volume | 90 |
| Issue number | 36 |
| DOIs | |
| State | Published - 28 Sep 2010 |
Keywords
- Antigens, CD30
- Graft rejection
- HLA antigens
- Immune status
- Kidney transplantation
Fingerprint
Dive into the research topics of 'Evaluation of immune status of kidney transplant recipients by combined HLA-G5 and sCD30'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver